Market Research Report

A quick peek into the report

Global CAR T-Cell Therapy Market

Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Some Faq's

Frequently Asked Questions

A. The Car T-Cell therapy market is projected to grow at the CAGR of 44.79% during the forecast period from 2020-2030. It is expected to reach $43.04 Billion by the end of 2030.

A. Factors restraining the growth of the market include high treatment cost of car t-cell therapy and side-effects of car T-cell therapy.

A. Some of the applications of CAR T-Cell therapy include diffuse large b-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and others

A. Therapy approval, manufacture quality control, efficacy and quality-adjusted life-year (qaly) assessment, safety assessment, pricing and patient access, and reimbursement are the challenges present in the CAR T-Cell Therapy.

A. The list of companies present in the market include Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.

Similar Product

You may also like

Global Cell and Gene Therapy Market
Published Year: 2019

Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landsc

The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a...